# Shanghai SIMR Biotech Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-simr-biotech-co

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.simrbio.com
- Total disclosed funding: $26M
- Latest round: Series C (Nov 8, 2022)
- Investors on record: 10

## About

Based in Shanghai, China, and established in 2014, Shanghai SIMR Biotech Co., Ltd is a new drug research and development company that provides new drugs for pain, inflammation, and central nervous system-related diseases. It established a R&D centre, covering more than 3,000 square meters, where it can do compound drug screening, chemical manufacture and control (CMC) research, preclinical evaluation, and clinical development. Moreover, it has branches in Guangdong, Jiangsu, Australia, and America.

Shanghai SIMR Biotech Co., Ltd provides new drugs for pain, inflammation, anti-depressant, and central nervous system-related diseases. Its pipeline products, SR419, and SR750 are used for neuropathic pain, and SR1375 is used for diabetic macular edema. SR419 has entered clinical phase II, and SR750 and SR1375 have entered clinical phase I. Depression drugs, chronic pain drugs, and Alzheimer drugs have been in the discovery phase. There is a translational centre focusing on brain science and technology.

## Funding rounds

- Series C, Nov 8, 2022, $21M — Tian Rui Feng Nian Private Fund, Guanzi Private Equity Management (Hangzhou), Jieyi Investment
- Series B, Oct 18, 2021, $4.7M — GF Xinde Investment, Efung Capital, Shanghai Zhangjiang Haocheng Venture Capital, Grand China Capital, Zhangjiang Haoheng Capital
- Series B, Jan 9, 2021 — Gaolin Capital Management, FC Capital - China

## Investors

- Gaolin Capital Management (https://capitalatlas.ai/funds/gaolin-capital-management) — Series B
- FC Capital - China (https://capitalatlas.ai/funds/fc-capital-china) — Series B
- GF Xinde Investment (https://capitalatlas.ai/funds/gf-xinde-investment) — Series B
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series B
- Shanghai Zhangjiang Haocheng Venture Capital (https://capitalatlas.ai/funds/shanghai-zhangjiang-haocheng-venture-capital) — Series B
- Grand China Capital (https://capitalatlas.ai/funds/grand-china-capital) — Series B
- Zhangjiang Haoheng Capital (https://capitalatlas.ai/funds/zhangjiang-haoheng-capital) — Series B
- Tian Rui Feng Nian Private Fund (https://capitalatlas.ai/funds/tian-rui-feng-nian-private-fund) — Series C
- Guanzi Private Equity Management (Hangzhou) — Series C
- Jieyi Investment — Series C